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Available online 18 April 2014We would agree with Professor Taylor that the role of metha-
crylic acid co-polymer (used as an enteric coating, Eudragit, in
certain brands of pancreatic enzymes) in developing fibrosing
colonopathy (FC) is unclear and controversial [1].
The initial clinical report and subsequent epidemiological
study linking FC to certain brands of high strength enzymes
formed the basis of the subsequent advice of the Committee on
Safety of Medicines (CSM)/Medicine control Agency (MCA)
[2–4]. It was advised that the high strength enzymes Pancrease
HL, Nutrizym 22 and Panzytrat 25,000 should not be used in
children aged 15 years or less with cystic fibrosis (CF) and
doses of more than 10,000 IU lipase per kg body weight per
day of any preparation should be avoided. Since this advice,
only three CF children in the UK have developed FC [5]. All
were receiving Nutrizym GR, a low strength preparation but
coated with Eudragit.
In contrast, in the US, advice was to avoid high strength
preparations containing more than 20,000 IU lipase per capsule
and a total lipase intake ofmore than 10,000 IU/kg/day; there was
no advice on brands [6]. However, despite this advice cases of
FC continued to be reported to the US CF Foundation [7].
There appear to be other factors that are relevant to the
development of cases of FA. From the evidence available,
Eudragit may have contributed and avoidance has resulted in the
disappearance of FC in children in the UK.
It has been suggested that a high intake of lipase in itself is
not a risk factor in the absence of methacrylic acid copolymer
[8,9]. This seems to be supported by the absence of further
UK cases despite the continuing high intake of predominantly
Creon preparations in the UK, both standard and high strength
[10], and Creon 25,000 in one paediatric CF centre [11].⁎ Corresponding author. Tel.: +44 1132067179.
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1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. AAs the vast majority of children with FC had been receiving
well in excess of 10,000 IU lipase/kg/day, we would reinforce
Professor Taylor's advice to continue to follow the guidelines
of the MCA/CSM [2,3,12].
Yours sincerely,
Dr Daniel Peckham
Dr Paul Whitaker
Consultant Respiratory Physicians
We would like to acknowledge the personal communication
with Dr James Littlewood OBE and the History of Cystic Fibrosis
Medicine.
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